Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Age-related Macular Degeneration (AMD) drugs market was valued at USD 7.90 billion in 2024 and is projected to reach USD 10.71 billion by 2031, exhibiting a CAGR of 4.5% during the forecast period.
AMD drugs are therapeutic agents designed to slow or prevent the progression of age-related macular degeneration, a leading cause of vision loss in older adults. These drugs primarily target neovascularization (wet AMD) through anti-VEGF agents and address geographic atrophy (dry AMD) through novel complement inhibitors and antioxidant therapies. The increasing global elderly population, rising prevalence of retinal diseases, and advancements in ophthalmic drug delivery systems are key drivers for this market.
The market is experiencing steady growth due to several factors, including the increasing global geriatric population, rising incidence of age-related eye diseases, and growing awareness about early treatment. Furthermore, advancements in gene therapy and sustained-release drug delivery systems present significant growth opportunities. However, high treatment costs and limited access in developing regions remain challenges. In February 2024, the U.S. FDA approved Apellis Pharmaceuticals' Syfovre (pegcetacoplan), the first treatment for geographic atrophy, demonstrating continued innovation in this space.
Major players in this market include Regeneron Pharmaceuticals, Roche Holding (Genentech), Novartis, Bayer, Biogen, Alimera Sciences, Adverum Biotechnologies, Eyepoint Pharmaceuticals, Outlook Therapeutics, Apellis Pharmaceuticals, and Amgen, among others.
Rising Geriatric Population Globally
The increasing number of elderly individuals worldwide directly correlates with higher AMD prevalence rates, as age is the primary risk factor for developing macular degeneration. With over 1.5 billion people expected to be aged 65 or older by 2050, the patient pool for AMD drugs continues to expand significantly.
Advancements in Anti-VEGF Therapies
Continuous innovation in anti-VEGF injections, including longer-lasting formulations and improved delivery mechanisms, has increased treatment efficacy while reducing injection frequency. Drugs like aflibercept and ranibizumab have shown significant success in preserving vision, creating sustained demand.
➤ The global AMD drugs market is projected to reach $12.8 billion by 2030, driven by both demographic trends and pharmaceutical innovation.
Growing healthcare expenditure in developed countries enables better access to these high-cost therapies, with some countries offering partial or full coverage through national healthcare systems.
MARKET CHALLENGES
High Treatment Costs and Accessibility Issues
The average cost of anti-VEGF injections ranges from $1,500 to $2,500 per injection, with patients typically requiring injections every 4 to 8 weeks indefinitely. This creates significant financial barriers, particularly in regions without comprehensive insurance coverage or in developing nations with limited healthcare budgets.
Other Challenges
Treatment Adherence and Monitoring Challenges
AMD treatment requires regular monitoring and strict adherence to treatment schedules, which can be challenging for elderly patients with mobility issues or other age-related health complications. Missed treatments can lead to disease progression and vision deterioration.
Stringent Regulatory Requirements for Biologics
Developing and approving new AMD drugs involves complex regulatory pathways, particularly for biologic drugs that require extensive clinical trials and post-market surveillance. The average development cost for a new biologic exceeds $2.5 billion, creating significant barriers to new market entrants and limiting competition that could drive prices down.
Emerging Markets and Untapped Populations
As developing economies improve their healthcare infrastructure and insurance coverage expands, previously underserved populations gain access to AMD treatments. Countries like China, India, and Brazil represent massive potential markets where aging populations are only beginning to receive adequate eye care, creating opportunities for market expansion.
Gene Therapy and Long-acting Formulations
Next-generation treatments including gene therapies that could provide longer-lasting effects with fewer injections represent a significant growth opportunity. Companies developing one-time treatments rather than chronic medications could capture substantial market share while reducing healthcare system burdens.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Anti-VEGF Injections represent the therapeutic backbone with superior efficacy in controlling disease progression. Gene therapies are emerging as transformative alternatives with potential long-term benefits. |
| By Application |
|
Wet AMD Treatment dominates the therapeutics landscape due to its aggressive nature and immediate threat to vision. Dry AMD management focuses on slowing progression and symptom management. |
| By End User |
|
Hospitals & Clinics represent the primary treatment centers offering comprehensive care and advanced diagnostic capabilities. Specialty Eye Centers provide highly specialized care with state-of-the-art equipment and specialized ophthalmologists. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
Roche Holding AG (Switzerland) maintains its leadership position through its blockbuster drug Lucentis (ranibizumab), which continues to capture significant market share despite biosimilar pressures. The company's strong R&D pipeline and geographic expansion strategies keep it at the forefront of AMD treatment.
Novartis AG (Switzerland) leverages its global presence to distribute anti-VEGF therapies, while Regeneron Pharmaceuticals Inc. (US) continues to innovate with Eylea (aflibercept), capturing substantial market share in key markets. Both companies invest heavily in next-generation therapies including gene therapies.
Emerging players like Samsung Bioepis (South Korea) are developing biosimilar alternatives that could disrupt the market dynamics, while smaller biotech firms focus on novel drug delivery systems to reduce treatment frequency and improve patient compliance.
Key players are actively pursuing strategic partnerships and licensing agreements to expand their geographic presence, particularly in emerging Asian markets where the aging population presents significant growth opportunities. Investments in predictive biomarkers also represent a growing competitive front.
List of Key Age-related Macular Degeneration Companies ProfiledRoche Holding AG (Switzerland)
Novartis AG (Switzerland)
Regeneron Pharmaceuticals Inc. (US)
Bayer AG (Germany)
Novartis AG (Switzerland)
Anti-VEGF drugs remain the cornerstone of AMD treatment, with ranibizumab and aflibercept capturing significant market share. The global market for these therapeutics reached $7.2 billion in 2023, with projected growth to $9.8 billion by 2028. Emerging biosimilars are creating pricing pressure while increasing treatment accessibility across developed markets.
Other TrendsGene Therapy Advancements
Gene therapy approaches are showing promising results in clinical trials, with several candidates entering phase III trials. Investments in ocular gene therapies reached $1.3 billion in 2023, driven by the potential for one-time treatments that could reduce or eliminate the need for chronic anti-VEGF injections. Major pharmaceutical companies are actively acquiring or partnering with biotech firms specializing in ocular gene therapies.
Combination therapies targeting multiple pathways simultaneously are demonstrating improved efficacy rates compared to monotherapies. The combination of anti-VEGF agents with complement inhibitors shows particular promise, with several Phase III trials reporting 30-40% better outcomes in geographic atrophy secondary to AMD. Regulatory agencies are creating accelerated pathways for these combination therapies, with two receiving breakthrough therapy designation in major markets.
Regional Market Dynamics
North America maintains the largest market share at 48%, driven by higher treatment adoption rates and premium pricing for novel therapies. Europe follows at 32%, with growth accelerating due to aging population demographics. The Asia-Pacific region shows the fastest growth at 17.2% CAGR, driven by increasing diagnosis rates and healthcare infrastructure development. Reimbursement policies continue to evolve across all regions, with 78% of developed markets now covering at least one anti-VEGF therapy through public or private insurance.
The dry AMD segment represents the largest untapped market opportunity, with several late-stage candidates showing promise. Recent Phase III results indicate potential for slowing geographic atrophy progression by up to 30% compared to standard care. Regulatory agencies are providing accelerated review pathways for these therapies, with first approvals expected within 18-24 months. Market analysts project dry AMD therapies could capture $4-6 billion in annual revenue within five years of launch, representing both a significant patient benefit and substantial market expansion.
Regional Analysis: Age-related Macular Degeneration Drugs MarketEurope
European markets maintain strong regulatory frameworks that ensure treatment quality while controlling costs. Countries with advanced healthcare systems like Germany and France achieve excellent outcomes through standardized treatment protocols and multidisciplinary care teams. The region shows gradual shift toward earlier intervention strategies and personalized treatment approaches based on genetic factors. Cross-border collaboration facilitates best practice sharing and accelerates adoption of innovative therapies.
Asia-Pacific
The region demonstrates exceptional growth driven by increasing disease prevalence and improving economic conditions. Japan and Australia represent mature markets with advanced treatment protocols, while developing nations show rapid infrastructure development. Telemedicine initiatives help extend specialist access to remote areas, though treatment consistency remains challenging. Governments increasingly recognize AMD as priority health issue and allocate resources accordingly.
Latin America
Market growth remains steady though constrained by economic fluctuations and currency instability. Countries with stronger economies like Brazil, Mexico, and Argentina maintain better treatment access through public-private partnerships, while smaller economies struggle with resource allocation. Regional cooperation initiatives help standardize care and reduce treatment cost through knowledge sharing and bulk purchasing agreements.
Middle East & Africa
Market development shows extreme variation between regions. Gulf states achieve near-complete treatment access through oil revenue investments in healthcare, while sub-Saharan Africa faces significant challenges. International aid organizations play crucial role in building infrastructure and training programs. Growing middle-class in urban centers drives private sector investment, though rural areas remain significantly underserved with limited access to advanced therapies.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Age-related Macular Degeneration Drugs market was valued at USD 7905 million in 2024 and is projected to reach USD 10710 million by 2031.
Which key companies operate in Global Age-related Macular Degeneration Drugs Market?
-> Key players include Regeneron Pharmaceuticals, Roche Holding, Novartis, Bayer, Biogen, Alimera Sciences, Adverum Biotechnologies, Eyepoint Pharmaceuticals, Outlook Therapeutics, Apellis Pharmaceuticals, and Amgen, among others.
-> Key growth drivers include an increasing global geriatric population, rising incidence of age-related eye diseases, and growing awareness about early treatment.
-> The market is expected to exhibit a CAGR of 4.5% during the forecast period 2024-2031.
-> Emerging trends include advancements in gene therapy, sustained-release drug delivery systems, and the approval of novel treatments for geographic atrophy.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates